SCHEMBL20119671

SCHEMBL20119671

Fc1cccc(CCNc2ncnc3[nH]cnc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.52
▸ AURKB Q96GD4 2/20 0.52
▸ BTK Q06187 2/20 0.52
▸ MAP4K4 O95819 2/20 0.52
▸ DAPK3 O43293 1/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ PAK4 O96013 1/20 0.52
▸ ABL1 P00519 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ CSF1R P07333 1/20 0.52
▸ RET P07949 1/20 0.52
▸ PDGFRB P09619 1/20 0.52
▸ FGFR1 P11362 1/20 0.52
▸ PRKACA P17612 1/20 0.52
▸ FLT1 P17948 1/20 0.52
▸ LTK P29376 1/20 0.52
▸ GRK5 P34947 1/20 0.52
▸ KDR P35968 1/20 0.52
▸ MAP2K2 P36507 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL621253 0.87 CLK4 (0.67) AURKAAURKBBTKMAP4K4DAPK3
SCHEMBL20119574 0.85 POLB (0.47) AURKABTKHTTTAAR1MAPK1
SCHEMBL20119580 0.84 AURKA (0.45) AURKAAURKBBTKKDRMAPK8
SCHEMBL17933849 0.84 HTT (0.49) MAP4K4HTTTAAR1MAPK1RPS6KB1
SCHEMBL9609211 0.84 MAPK1 (0.64) HTTTAAR1MAPK1SLC29A1MAPT
SCHEMBL20119570 0.82 TP53 (0.62) AURKAHTTTAAR1MAPK1RPS6KB1
SCHEMBL2019257 0.80 LMNA (0.41) AURKAAURKBBTKMAP4K4DAPK3
SCHEMBL30850528 0.79 HTT (0.48) FGFR1KDRDYRK1AHTTTAAR1
SCHEMBL20119357 0.79 HTT (0.48) FGFR1KDRDYRK1AHTTTAAR1
SCHEMBL30850642 0.78 HTT (0.49) HTTTAAR1MAPK1SLC29A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 — — US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 — — US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 AURKA 4532/4885AURKB 3639/4885BTK 4846/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 AURKA 4532/4885AURKB 3639/4885BTK 4846/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 AURKA 4532/4885AURKB 3639/4885BTK 4846/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 AURKA 4532/4885AURKB 3639/4885BTK 4846/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 AURKA 4532/4885AURKB 3639/4885BTK 4846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback